This study is testing a new approach for people with metastatic cancer (cancer that has spread from its original site). It uses two special drugs: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. First, you would have a scan using [68Ga]Ga DOTA-5G to see if your cancer lights up, which helps determine if the second drug, [177Lu]Lu DOTA-ABM-5G, might be effective for you. If it does, you would then receive the [177Lu]Lu DOTA-ABM-5G therapy. This study aims to see if these drugs are safe and if they can help treat metastatic cancers, including those from the GU (genitourinary), GI (gastrointestinal), GYN (gynecological), breast, cervical, uterine, or head and neck areas. The study plans to enroll up to 40 participants.

Study design

This is a Phase I interventional study, meaning it's an early-stage study to test safety and dosage. It plans to enroll up to 40 participants.

What's involved

You would undergo a [68Ga]Ga DOTA-5G PET/CT scan. If eligible, you would then receive the [177Lu]Lu DOTA-ABM-5G therapy.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, [68Ga]Ga DOTA-5G PET/CT imaging, is measured at 2 hours from the time of injection. The overall follow-up duration is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.